PriceTargets.com logo

Onconetix - ONCO Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.95 As of 12/4/2025 04:59 PM ET
▼ -0.04 (-1.34%)

This chart shows the closing price for ONCO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Onconetix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Onconetix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.95.

This chart shows the closing price for ONCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in Onconetix.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Onconetix logo
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Read More

Today's Range

Now: $2.95
Low: $2.92
High: $3.15

50 Day Range

MA: $3.05
Low: $2.21
High: $4.12

52 Week Range

Now: $2.95
Low: $2.10
High: $179.35

Volume

37,815 shs

Average Volume

29,886 shs

Market Capitalization

$4.60 million

P/E Ratio

0.27

Dividend Yield

N/A

Beta

3.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Onconetix?

The following Wall Street sell-side analysts have issued reports on Onconetix in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ONCO.

What is the current price target for Onconetix?

0 Wall Street analysts have set twelve-month price targets for Onconetix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Onconetix in the next year.
View the latest price targets for ONCO.

What is the current consensus analyst rating for Onconetix?

Onconetix currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe ONCO will underperform the market and that investors should sell shares of Onconetix.
View the latest ratings for ONCO.

What other companies compete with Onconetix?

Other companies that are similar to Onconetix include Pulmatrix, Chemomab Therapeutics, Soligenix, Cellectar Biosciences and Apollomics. Learn More about companies similar to Onconetix.

How do I contact Onconetix's investor relations team?

Onconetix's physical mailing address is 201 East Fifth Street, Suite 1900, Cincinnati, OH 45202, United States. The company's listed phone number is 513-620-4101 and its investor relations email address is [email protected]. The official website for Onconetix is www.bwbioinc.com. Learn More about contacing Onconetix investor relations.